These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
17. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. Xie H; Jiang W; Xiao SY; Liu X J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer. Maisonneuve P; Lowenfels AB JAMA; 2007 Jun; 297(23):2581; author reply 2582. PubMed ID: 17579223 [No Abstract] [Full Text] [Related]
19. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas. Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919 [TBL] [Abstract][Full Text] [Related]
20. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]